The First and Only FDA Approved Product to Relieve Symptoms and Signs of Onychodystrophy
Genadur® is proven to:
Formulated to address fragile, brittle or split nails caused by:
Unique hydrosoluble nail lacquer formulation containing hydroxypropyl-chitosan (HPCH), equisetum arvense and methyl sulfonyl methane (MSM)
Genadur® showed 85% reduction in patients reporting lamellar splitting of treated nails, while no significant change was observed in untreated controls
Genadur® showed 90% of cases with 1 grade improvement in nail fragility after 14 days
Genadur® showed a statistically significant improvement in patients with mild-to-moderate nail psoriasis
IMPORTANT SAFETY INFORMATION
Genadur® is for external use only. Eye contact should be avoided. It is contraindicated in patients with known hypersensitivity to any of the components. Please see full prescribing information.
RX - Prescription Medical Device: Federal Law restricts this device to sale by or on the order of a physician.
1Journal of Plastic Dermatology 2006: Vol. 2, n. 1 January-April. Equisetum averense in a New Transungual Technology Improves Nail Structure and Appearance. Sparavigna A, Setaro M, Genet M, Frisenda L.
2Journal of the Euopean Academy of Dermatology and Venereology2009: Vol. 23, n. 7 July. Improvement of Psoriatic Onychodystrophy by a Water-soluble Nail Lacquer. Cantoresi, P, Sorgi P, Arcese A, Bidoli A, Bruni F, Canevale C, Calvieri S.
3Journal of American Academy of Dermatology 2005: Vol. 53, October, Brittle Nail System: A Pathogenesis-based Approach with a Proposed Grading System, van de Kerkhof P, Pasch M, Scher R, Kerscher M, Gieler U, Haneke E, Fleckman, P.
Medimetriks Pharmaceuticals, Inc.
383 Route 46 West
Fairfield, NJ 07004-2402 USA